Genmab A/S (OTCMKTS:GNMSF) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Genmab A/S (OTCMKTS:GNMSF) from a hold rating to a buy rating in a research report report published on Wednesday, Zacks.com reports. They currently have $202.00 price target on the stock.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
OTCMKTS:GNMSF traded up $0.59 on Wednesday, hitting $177.84. The stock had a trading volume of 309 shares, compared to its average volume of 1,177. The firm has a market capitalization of $10.90 billion, a PE ratio of 57.40 and a beta of 0.16. The stock has a fifty day moving average price of $177.76. Genmab A/S has a 1-year low of $119.10 and a 1-year high of $186.30.
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Article: Find a Trading Strategy That Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.